Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bristol Looking For Deals, Immuno-Oncology And Otherwise

This article was originally published in The Pink Sheet Daily

Executive Summary

Business development is a top priority for Bristol, management said during the company’s second quarter earnings call, and the focus is on expanding in immuno-oncology portfolio and other core therapeutic areas.

You may also be interested in...



Bristol/Medarex: A Transformational Acquisition Rooted In Collaboration

Bristol's $2.4 billion buyout of Medarex in 2009 yielded value equivalent or greater to that realized in larger M&A transactions signed that year, such as Pfizer/Wyeth, Merck/Schering-Plough and Roche/Genentech. The deal made BMS a leader in immuno-oncology and by most accounts is the highlight of the pharma's "string of pearls" strategy.

Emerging Markets Earnings Roundup: Bristol Myers Squibb (Part 6)

Bristol Myers Squibb saw some turbulence for Baraclude sales in China and Japan, but noted Yervoy sales lifted and the company has high hopes for a deal with Ono and its Opdivo oncology treatment.

Celldex Differentiated Immuno-Oncology Asset Ripe For Combos

Celldex Therapeutics will initiate Phase I/II trials of its immunotherapy varlilumab in combination with Bristol’s PD-1 inhibitor nivolumab this year and is exploring multiple other combinations.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS077480

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel